Heart Failure Treatment Pattern Analysis of HF Patients in HF Centers and Non-HF Centers in China

Completed

• Conditions: Heart Failure
• Interventions: Other: no intervention

• Registration Number: NCT06099028
• Lead Sponsor: Peking University First Hospital

Brief Summary

This is a retrospective, researcher-initiated, database-based study that will retrospectively observe the treatment and medication patterns of about 22,500 patients with heart failure from 25 heart failure centers and 25 non-heart failure centers in the database of heart failure center. The proportion of patients with heart failure treatment drugs reaching the target dose recommended in the guidelines and discontinuation rate will be observed at 1 month, 3 months and 12 months follow up time point. The purpose of this study is to illustrate the current HF treatment status in HF center hospitals and non-HF center hospitals, which may provide insights for improving the clinical practice of heart failure treatment in China, and promote the standardization of heart failure treatment in China.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-09-01
• Primary Completion: 2023-03-31
• Study Completion: 2023-03-31
• Study First Submitted: 2023-09-17
• Study First Submitted QC: 2023-10-22
• Study First Posted: 2023-10-25
• Status Verified: 2024-01
• Last Update Submitted: 2024-01-21
• Last Update Posted: 2024-01-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 22500

Inclusion Criteria

• An index HF diagnosis date in the records
• Age ≥ 18 years old at initial diagnosis date
• HF patients baseline characteristic record

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
HF center	no intervention	heart failure patients enrolled from heart failure center hospitals

Primary Outcome Measures

Name	Time	Method
Number of GDMT drugs (classified as RAASi (including ARNI), beta blockers, MRA and SGLT2i)	At baseline and at 1 month, 3 month, 12 month follow-up time point	Numbers of GDMT drugs of HF patients stratified by HF ejection fraction and by HF Center and Non-HF Center
Use rates of GDMT drugs	At baseline and at 1 month, 3 month, 12 month follow-up time point	The percentage of patients using each GDMT drug，stratified by HF ejection fraction and by HF Center and Non-HF Center

Secondary Outcome Measures

Name	Time	Method
Discontinuation rate of each GDMT drug	at 1 month, 3 month, 12 month follow-up time point	The percentage of patients who discontinued GDMT drugs, stratified by HF ejection fraction and by HF Center and Non-HF Center
The proportion of patients using 2 types of GDMT drugs	At baseline and at 1 month, 3 month, 12 month follow-up time point	The percentage of patients using 2 of any 4 GDMT drugs，stratified by HF ejection fraction and by HF Center and Non-HF Center
The proportion of patients using 3 types of GDMT drugs	At baseline and at 1 month, 3 month, 12 month follow-up time point	The percentage of patients using 3 of any 4 GDMT drugs，stratified by HF ejection fraction and by HF Center and Non-HF Center
The proportion of patients using 4 types of GDMT drugs	At baseline and at 1 month, 3 month, 12 month follow-up time point	The percentage of patients using all types of GDMT drugs，stratified by HF ejection fraction and by HF Center and Non-HF Center
The proportion of patients with each GDMT drug in the target dose	at 1 month, 3 month, 12 month follow-up time point	The percentage of patients who achieved the target dose of each GDMT drug, stratified by HF ejection fraction and by HF Center and Non-HF Center

Trial Locations

Locations (1)

Department of Cardiology, Peking University First Hospital; 🇨🇳 Beijing, China